stockrow
Saturday 7 November 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
- EPS
- +30.2%
- Free cash flow
- −13.2%
Quarter to September 2026, against a year earlier
0.36
0.04
+12.50%
Follow TNYA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (148.16%) | (121.86%) | (73.59%) | (83.84%) |
+8 more TTM periods Free account |
|
| (112.05%) | (95.61%) | (59.50%) | (67.90%) | ||
ROIC |
0.00% | 0.00% | (212.08%) | (256.77%) | |
Return on Tangible Assets |
(190.79%) | (148.41%) | (78.50%) | (76.89%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.24) | (0.24) | (0.30) | (0.45) | |
Free Cash Flow |
(54.62) | (52.59) | (64.63) | (68.88) | |
Capital Expenditures |
(0.21) | (0.26) | (0.25) | (0.62) | |
| Other line items | |||||
Cash ROIC |
(45.02%) | (35.65%) | (34.55%) | (30.78%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.53 | 0.51 | 0.78 | 0.75 | |
Depreciation/Fixed assets |
5.00 | 2.91 | 0.31 | 0.32 | |
Capex/Depreciation |
(0.04) | (0.04) | (0.03) | (0.07) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.24) | (0.24) | (0.30) | (0.45) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026